Print
Email
Print Edition StoriesThursday, May 21, 2009
Cellceutix files for cancer compound patent
By Mass High Tech Staff
MHT's Marc Songini: RI plans launch of cord blood center
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Anti-angiogenesis drug company Cellceutix Pharma Inc. says it has filed a U.S. patent application covering formulations of a compound called Kevetrin, aimed at applications including cancer treatment.
The application also covers compounds having similar structures to Kevetrin, and Beverly-based Cellceutix says it will give them a large number of possible drug development candidates. Cellceutix officials say the company plans to file in other countries within a year of the U.S. filing.
According to CEO George Evans, Cellceutix has also been conducting experiments with Kevetrin and its psoriasis candidate, KM-133. The company states on its website that Kevetrin is primarily focused on the treatment of head and neck cancers.
Cellceutix says it owns the rights to six drug compounds, including Kevetrin and KM-133. The company is led by Evans, formerly with Pfizer (NYSE: PFE), and its president Krishna Menon, formerly with Eli Lilly (NYSE: LLY).
Cellceutix (OTCBB: CTIX), which trades on the Over the Counter Bulletin Board, took its initial funding in May of 2008, worth $400,000.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
